Model to estimate survival in ambulatory patients with hepatocellular carcinoma

Hepatology

Volumn 56, Issue 2, 2012, Pages 614-621

  Yang, Ju Dong ^a   Kim, W Ray ^a   Park, Kyung Woo ^b   Chaiteerakij, Roongruedee ^a   Kim, Bohyun ^c   Sanderson, Schuyler O ^c   Larson, Joseph J ^c   Pedersen, Rachel A ^c   Therneau, Terry M ^c   Gores, Gregory J ^a   Roberts, Lewis R ^a   Park, Joong Won ^b  

^a MAYO CLINIC   (United States)

^b National Cancer Center   (South Korea)

^c Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BARCELONA CLINIC LIVER CANCER; CANCER INVASION; CANCER OF THE LIVER ITALIAN PROGRAM; CANCER SIZE; CANCER SURVIVAL; COHORT ANALYSIS; END STAGE LIVER DISEASE; EXTERNAL VALIDITY; FEMALE; HUMAN; INTERNAL VALIDITY; JAPAN INTEGRATED STAGING; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MODEL FOR ENDSTAGE LIVER DISEASE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SCORING SYSTEM; VIRUS HEPATITIS;

AGED; AMBULATORY CARE; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RISK FACTORS;

EID: 84864351661     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25680     Document Type: Article

References (21)

1. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 2010; 7: 448-458.
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-1491.
3. Kim WR, Gores GJ, Benson JT, Therneau TM, Melton LJ 3rd. Mortality and hospital utilization for hepatocellular carcinoma in the United States. Gastroenterology 2005; 129: 486-493.
4. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
5. [No authors listed.] A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. HEPATOLOGY 1998; 28: 751-755.
6. [No authors listed.] Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) investigators. HEPATOLOGY 2000; 31: 840-845.
7. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003; 38: 207-215.
8. Lei HJ, Chau GY, Lui WY, Tsay SH, King KL, Loong CC, et al. Prognostic value and clinical relevance of the 6th Edition 2002 American Joint Committee on Cancer staging system in patients with resectable hepatocellular carcinoma. J Am Coll Surg 2006; 203: 426-435.
9. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 918-928.
10. Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002; 94: 1760-1769.
11. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999; 31: 133-141.
12. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. HEPATOLOGY 2001; 33: 464-470.
13. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). HEPATOLOGY 2007; 45: 797-805.
14. Bruix J, Sherman M. Management of hepatocellular carcinoma. HEPATOLOGY 2005; 42: 1208-1236.
15. Yang JD, Kim WR, Coelho R, Mettler TA, Benson JT, Sanderson SO, et al. Cirrhosis is present in most patients with hepatitis b and hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011; 9: 64-70.
16. Park KW, Park JW, Choi JI, Kim TH, Kim SH, Park HS, et al. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol 2008; 23: 467-473.
17. Park JW. [Practice guideline for diagnosis and treatment of hepatocellular carcinoma.] Korean J Hepatol 2004; 10: 88-98.
18. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-96.
19. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. HEPATOLOGY 2005; 41: 707-716.
20. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med 1999; 130: 515-524.
21. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.